Compare CARE & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CARE | PRTA |
|---|---|---|
| Founded | 1974 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 507.1M | 539.9M |
| IPO Year | 2020 | 2013 |
| Metric | CARE | PRTA |
|---|---|---|
| Price | $26.41 | $10.84 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $25.00 | $19.00 |
| AVG Volume (30 Days) | 311.5K | ★ 342.8K |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.40% | N/A |
| EPS Growth | ★ 30.19 | N/A |
| EPS | ★ 3.88 | 0.60 |
| Revenue | ★ $20,315,000.00 | $814,000.00 |
| Revenue This Year | $12.50 | $1,111.38 |
| Revenue Next Year | $11.82 | N/A |
| P/E Ratio | $19.00 | ★ N/A |
| Revenue Growth | ★ 4.65 | N/A |
| 52 Week Low | $15.48 | $4.32 |
| 52 Week High | $26.58 | $11.69 |
| Indicator | CARE | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 76.40 | 52.77 |
| Support Level | $19.34 | $9.81 |
| Resistance Level | N/A | $11.61 |
| Average True Range (ATR) | 0.68 | 0.51 |
| MACD | 0.06 | -0.07 |
| Stochastic Oscillator | 92.51 | 25.71 |
Carter Bankshares Inc is a bank holding company that conducts its business solely through the bank. The Bank earns revenue from interest on loans and securities and fees charged for financial services provided to customers. It offers a full range of deposit services including Lifetime Free Checking, interest checking accounts, savings accounts, retirement accounts and other deposit accounts of various types, ranging from money market accounts to longer-term CDs. The Bank offers a full range of commercial and consumer loans. The Bank also originates and holds fixed and variable-rate mortgage loans and offers home equity lines of credit to its customers.
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.